Stefan StevanoviÄ

List of Publications by Year
in descending order

		71102	69250
105 papers	6,759 citations	41 h-index	77 g-index
116 all docs	116 docs citations	116 times ranked	9659 citing authors

#	Article	IF	Citations
1	Dermcidin: a novel human antibiotic peptide secreted by sweat glands. Nature Immunology, 2001, 2, 1133-1137.	14.5	614
2	A vaccine targeting mutant IDH1 induces antitumour immunity. Nature, 2014, 512, 324-327.	27.8	613
3	SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition. Nature Immunology, 2021, 22, 74-85.	14.5	490
4	A vaccine targeting mutant IDH1 in newly diagnosed glioma. Nature, 2021, 592, 463-468.	27.8	232
5	Plantaricin W from Lactobacillus plantarum belongs to a new family of two-peptide lantibiotics The GenBank accession number for the sequence reported in this paper is AY007251.. Microbiology (United) Tj ETQq1 1 0.784314 rgBT /Ov	1.8	179
6	The peptide binding motif of the disease associated HLA-DQ (Î± 1* 0501, Î² 1* 0201) molecule. European Journal of Immunology, 1996, 26, 2764-2772.	2.9	154
7	Improved Ribo-seq enables identification of cryptic translation events. Nature Methods, 2018, 15, 363-366.	19.0	153
8	The immunopeptidomic landscape of ovarian carcinomas. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E9942-E9951.	7.1	152
9	HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL). Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E166-75.	7.1	150
10	HLA-DR15 Molecules Jointly Shape an Autoreactive T Cell Repertoire in Multiple Sclerosis. Cell, 2020, 183, 1264-1281.e20.	28.9	133
11	Identification of tumor-associated MHC class I ligands by a novel T cell-independent approach. European Journal of Immunology, 2000, 30, 2216-2225.	2.9	131
12	SYFPEITHI. Methods in Molecular Biology, 2007, 409, 75-93.	0.9	129
13	T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individuals. Science Translational Medicine, 2021, 13, .	12.4	128
14	HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy. , 2021, 9, e002071.		126
15	Identification of tumour-associated t-cell epitopes for vaccine development. Nature Reviews Cancer, 2002, 2, 514-514.	28.4	122
16	Distorted Relation between mRNA Copy Number and Corresponding Major Histocompatibility Complex Ligand Density on the Cell Surface. Molecular and Cellular Proteomics, 2007, 6, 102-113.	3.8	121
17	The SysteMHC Atlas project. Nucleic Acids Research, 2018, 46, D1237-D1247.	14.5	119
18	The endoplasmic reticulum-resident stress protein gp96 binds peptides translocated by TAP. European Journal of Immunology, 1997, 27, 923-927.	2.9	111

#	Article	IF	Citations
19	Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma. Genome Medicine, 2019, 11, 28.	8.2	107
20	An open-source computational and data resource to analyze digital maps of immunopeptidomes. ELife, 2015, 4, .	6.0	107
21	The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cellâ€“based immunotherapy. Blood, 2015, 126, 1203-1213.	1.4	103
22	Mapping the tumour human leukocyte antigen (HLA) ligandome by mass spectrometry. Immunology, 2018, 154, 331-345.	4.4	101
23	Cathepsin S and an asparagine-specific endoprotease dominate the proteolytic processing of human myelin basic proteinin vitro. European Journal of Immunology, 2001, 31, 3726-3736.	2.9	94
24	Biochemical Large-Scale Identification of MHC Class I Ligands. Methods in Molecular Biology, 2013, 960, 145-157.	0.9	91
25	TAPBPR alters MHC class I peptide presentation by functioning as a peptide exchange catalyst. ELife, 2015, 4, .	6.0	87
26	Toll-like receptor 2 activation depends on lipopeptide shedding by bacterial surfactants. Nature Communications, 2016, 7, 12304.	12.8	86
27	Mouse urinary peptides provide a molecular basis for genotype discrimination by nasal sensory neurons. Nature Communications, 2013, 4, 1616.	12.8	81
28	Unveiling the Peptide Motifs of HLA-C and HLA-G from Naturally Presented Peptides and Generation of Binding Prediction Matrices. Journal of Immunology, 2017, 199, 2639-2651.	0.8	81
29	Personalized peptide vaccine-induced immune response associated with long-term survival of a metastatic cholangiocarcinoma patient. Journal of Hepatology, 2016, 65, 849-855.	3.7	75
30	Promiscuous survivin peptide induces robust CD4⁺ Tâ€cell responses in the majority of vaccinated cancer patients. International Journal of Cancer, 2012, 131, 140-149.	5.1	70
31	TAPBPR bridges UDP-glucose:glycoprotein glucosyltransferase 1 onto MHC class I to provide quality control in the antigen presentation pathway. ELife, 2017, 6, .	6.0	66
32	MHC-I Ligand Discovery Using Targeted Database Searches of Mass Spectrometry Data: Implications for T-Cell Immunotherapies. Journal of Proteome Research, 2017, 16, 1806-1816.	3.7	65
33	Identification of non-mutated neoantigens presented by TAP-deficient tumors. Journal of Experimental Medicine, 2018, 215, 2325-2337.	8.5	64
34	Excreted Cytoplasmic Proteins Contribute to Pathogenicity in Staphylococcus aureus. Infection and Immunity, 2016, 84, 1672-1681.	2.2	60
35	An impedance-based cytotoxicity assay for real-time and label-free assessment of T-cell-mediated killing of adherent cells. Journal of Immunological Methods, 2014, 405, 192-198.	1.4	59
36	The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy. Blood, 2019, 133, 550-565.	1.4	57

#	Article	IF	Citations
37	Mapping the HLA Ligandome of Colorectal Cancer Reveals an Imprint of Malignant Cell Transformation. Cancer Research, 2018, 78, 4627-4641.	0.9	56
38	Cutting Edge: Predetermined Avidity of Human CD8 T Cells Expanded on Calibrated MHC/Anti-CD28-Coated Microspheres. Journal of Immunology, 2003, 171, 4974-4978.	0.8	53
39	Potent costimulation of human CD8 T cells by anti-4-1BB and anti-CD28 on synthetic artificial antigen presenting cells. Cancer Immunology, Immunotherapy, 2007, 57, 175-183.	4.2	50
40	Interaction analyses of human monocytes co-cultured with different forms of Aspergillus fumigatus. Journal of Medical Microbiology, 2009, 58, 49-58.	1.8	50
41	TAPBPR mediates peptide dissociation from MHC class I using a leucine lever. ELife, 2018, 7, .	6.0	46
42	Identification of a new HLA-A*0201-restricted T-cell epitope from the tyrosinase-related protein 2 (TRP2) melanoma antigen. International Journal of Cancer, 2000, 87, 399-404.	5.1	45
43	Dipeptides catalyze rapid peptide exchange on MHC class I molecules. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 202-207.	7.1	45
44	Immunological long-term follow-up of neuroblastoma stage IV patients after anti-GD2 CH14.18 antibody treatment.. Journal of Clinical Oncology, 2015, 33, 3029-3029.	1.6	45
45	Purification and Identification of Naturally Presented MHC Class I and II Ligands. Methods in Molecular Biology, 2019, 1988, 123-136.	0.9	44
46	HLA ligandome analysis of primary chronic lymphocytic leukemia (CLL) cells under lenalidomide treatment confirms the suitability of lenalidomide for combination with T-cell-based immunotherapy. OncoImmunology, 2018, 7, e1316438.	4.6	42
47	A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer. , 2019, 7, 307.		39
48	Allo- and self-restricted cytotoxic T lymphocytes against a peptide library: evidence for a functionally diverse allorestricted T cell repertoire. European Journal of Immunology, 1998, 28, 2432-2443.	2.9	38
49	Measles Virus-Based Treatments Trigger a Pro-inflammatory Cascade and a Distinctive Immunopeptidome in Glioblastoma. Molecular Therapy - Oncolytics, 2019, 12, 147-161.	4.4	38
50	The natural HLA ligandome of glioblastoma stem-like cells: antigen discovery for T cell-based immunotherapy. Acta Neuropathologica, 2018, 135, 923-938.	7.7	36
51	BTK operates a phospho-tyrosine switch to regulate NLRP3 inflammasome activity. Journal of Experimental Medicine, 2021, 218, .	8.5	33
52	Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy. Genome Medicine, 2020, 12, 32.	8.2	32
53	Mild Acid Elution and MHC Immunoaffinity Chromatography Reveal Similar Albeit Not Identical Profiles of the HLA Class I Immunopeptidome. Journal of Proteome Research, 2021, 20, 289-304.	3.7	32
54	Guidance Document: Validation of a High-Performance Liquid Chromatography-Tandem Mass Spectrometry Immunopeptidomics Assay for the Identification of HLA Class I Ligands Suitable for Pharmaceutical Therapies. Molecular and Cellular Proteomics, 2020, 19, 432-443.	3.8	31

#	Article	IF	Citations
55	A Non-interventional Clinical Trial Assessing Immune Responses After Radiofrequency Ablation of Liver Metastases From Colorectal Cancer. Frontiers in Immunology, 2019, 10, 2526.	4.8	29
56	High-density preculture of PBMCs restores defective sensitivity of circulating CD8 T cells to virus- and tumor-derived antigens. Blood, 2015, 126, 185-194.	1.4	28
57	HLA class I-restricted <i>MYD88</i> L265P-derived peptides as specific targets for lymphoma immunotherapy. OncoImmunology, 2017, 6, e1219825.	4.6	28
58	Targeting self- and neoepitopes with a modular self-adjuvanting cancer vaccine. JCI Insight, 2019, 4, .	5.0	28
59	HIV-1 induced changes in HLA-Câˆ—03â€Š:â€Š04-presented peptide repertoires lead to reduced engagement of inhibitory natural killer cell receptors. Aids, 2020, 34, 1713-1723.	2.2	28
60	Identification of HLA-A*01- and HLA-A*02-restricted CD8+ T-cell epitopes shared among group B enteroviruses. Journal of General Virology, 2008, 89, 2090-2097.	2.9	27
61	Multiplexed Relative Quantitation with Isobaric Tagging Mass Spectrometry Reveals Class I Major Histocompatibility Complex Ligand Dynamics in Response to Doxorubicin. Analytical Chemistry, 2019, 91, 5106-5115.	6.5	27
62	Low mutational load in pediatric medulloblastoma still translates into neoantigens as targets for specific T-cell immunotherapy. Cytotherapy, 2019, 21, 973-986.	0.7	25
63	Structural basis of immunogenicity. Transplant Immunology, 2002, 10, 133-136.	1.2	23
64	Identification of HLA ligands and T-cell epitopes for immunotherapy of lung cancer. Cancer Immunology, Immunotherapy, 2013, 62, 1485-1497.	4.2	22
65	Cathepsin G-mediated proteolytic degradation of MHC class I molecules to facilitate immune detection of human glioblastoma cells. Cancer Immunology, Immunotherapy, 2016, 65, 283-291.	4.2	22
66	Therapy-Induced MHC I Ligands Shape Neo-Antitumor CD8 T Cell Responses during Oncolytic Virus-Based Cancer Immunotherapy. Journal of Proteome Research, 2019, 18, 2666-2675.	3.7	22
67	Immunogenicity and Immune Silence in Human Cancer. Frontiers in Immunology, 2020, 11, 69.	4.8	22
68	A mutation-specific peptide vaccine targeting IDH1R132H in patients with newly diagnosed malignant astrocytomas: A first-in-man multicenter phase I clinical trial of the German Neurooncology Working Group (NOA-16).. Journal of Clinical Oncology, 2018, 36, 2001-2001.	1.6	21
69	Carcinogenesis of renal cell carcinoma reflected in HLA ligands: A novel approach for synergistic peptide vaccination design. OncoImmunology, 2016, 5, e1204504.	4.6	19
70	HLA ligandomics identifies histone deacetylase 1 as target for ovarian cancer immunotherapy. OncoImmunology, 2016, 5, e1065369.	4.6	18
71	HLA-A26 subtype A pockets accommodate acidic N-termini of ligands. Immunogenetics, 1998, 48, 350-353.	2.4	17
72	Results of a Phase 1/2 Study in Metastatic Renal Cell Carcinoma Patients Treated with a Patient-specific Adjuvant Multi-peptide Vaccine after Resection of Metastases. European Urology Focus, 2019, 5, 604-607.	3.1	17

#	Article	IF	Citations
73	GAPVAC-101: First-in-human trial of a highly personalized peptide vaccination approach for patients with newly diagnosed glioblastoma.. Journal of Clinical Oncology, 2018, 36, 2000-2000.	1.6	17
74	Characterization of the Canine MHC Class I DLA-88*50101 Peptide Binding Motif as a Prerequisite for Canine T Cell Immunotherapy. PLoS ONE, 2016, 11, e0167017.	2.5	17
75	Antileukemia T-cell responses in CLL â€“ We don't need no aberration. OncoImmunology, 2015, 4, e1011527.	4.6	15
76	HLA-B locus products resist degradation by the human cytomegalovirus immunoevasin US11. PLoS Pathogens, 2019, 15, e1008040.	4.7	15
77	Mass spectrometry-based identification of a B-cell maturation antigen-derived T-cell epitope for antigen-specific immunotherapy of multiple myeloma. Blood Cancer Journal, 2020, 10, 24.	6.2	15
78	In vitro effect of molluscan hemocyanins on CAL-29 and T-24 bladder cancer cell lines. Biomedical Reports, 2013, 1, 235-238.	2.0	14
79	The dominantly expressed class II molecule from a resistant MHC haplotype presents only a few Marekâ€™s disease virus peptides by using an unprecedented binding motif. PLoS Biology, 2021, 19, e3001057.	5.6	14
80	Identification of HCMV-derived T cell epitopes in seropositive individuals through viral deletion models. Journal of Experimental Medicine, 2020, 217, .	8.5	13
81	A meta-analysis of HLA peptidome composition in different hematological entities: entity-specific dividing lines and â€œpan-leukemiaâ€•antigens. Oncotarget, 2017, 8, 43915-43924.	1.8	12
82	Identification of MHC Ligands and Establishing MHC Class I Peptide Motifs. Methods in Molecular Biology, 2019, 1988, 137-147.	0.9	11
83	Antitumour activity of <i>Helix</i> hemocyanin against bladder carcinoma permanent cell lines. Biotechnology and Biotechnological Equipment, 2019, 33, 20-32.	1.3	10
84	Key Features Relevant to Select Antigens and TCR From the MHC-Mismatched Repertoire to Treat Cancer. Frontiers in Immunology, 2019, 10, 1485.	4.8	8
85	Mass spectrometry-based identification of a naturally presented receptor tyrosine kinase-like orphan receptor 1-derived epitope recognized by CD8 ⁺ cytotoxic T cells. Haematologica, 2017, 102, e460-e464.	3.5	7
86	Argyrin F Treatmentâ€Induced Vulnerabilities Lead to a Novel Combination Therapy in Experimental Glioma. Advanced Therapeutics, 2021, 4, 2100078.	3.2	7
87	Peptide-Based Sandwich Immunoassay for the Quantification of the Membrane Transporter Multidrug Resistance Protein 1. Analytical Chemistry, 2018, 90, 5788-5794.	6.5	6
88	A mutation-specific peptide vaccine targeting <i>IDH1R132H</i> in patients with newly diagnosed malignant astrocytomas: A first-in-man multicenter phase I clinical trial of the German Neurooncology Working Group (NOA-16).. Journal of Clinical Oncology, 2016, 34, TPS2082-TPS2082.	1.6	6
89	Integrin Activation Enables Sensitive Detection of Functional CD4+ and CD8+ T Cells: Application to Characterize SARS-CoV-2 Immunity. Frontiers in Immunology, 2021, 12, 626308.	4.8	5
90	The Impact of Biomaterial Cell Contact on the Immunopeptidome. Frontiers in Bioengineering and Biotechnology, 2020, 8, 571294.	4.1	5

#	Article	IF	Citations
91	Favorable immune signature in CLL patients, defined by antigen-specific T-cell responses, might prevent second skin cancers. Leukemia and Lymphoma, 2018, 59, 1949-1958.	1.3	4
92	Establishing MHC Class I Peptide Motifs. Methods in Molecular Biology, 2013, 960, 159-168.	0.9	2
93	Broad and Efficient Activation of Memory CD4+ T Cells by Novel HAdV- and HCMV-Derived Peptide Pools. Frontiers in Immunology, 2021, 12, 700438.	4.8	2
94	HLA Ligandome Analysis Of Chronic Myeloid Leukemia (CML), Revealed Novel Tumor Associated Antigens For Peptide Based Immunotherapy. Blood, 2013, 122, 3975-3975.	1.4	2
95	Mapping The HLA Ligandome Of Chronic Lymphocytic Leukemia â€“ Towards Peptide Based Immunotherapy. Blood, 2013, 122, 4123-4123.	1.4	1
96	Characterization Of The HLA Class II Ligandome In Acute Myeloid Leukemia (AML) Reveals Novel Candidates For Peptide-Based Immunotherapy. Blood, 2013, 122, 5012-5012.	1.4	1
97	Mapping the HLA Ligandome Landscape of Chronic Myeloid Leukemia Identifies Novel CD8+ and CD4+ T Cell-Epitopes for Immunotherapeutic Approaches. Blood, 2016, 128, 4232-4232.	1.4	1
98	IMMU-28. DECIPHERING THE AT/RT LIGANDOME. Neuro-Oncology, 2018, 20, i104-i104.	1.2	0
99	HLA Class I Ligandome Analysis In Acute Myeloid Leukemia â€“ Novel T-Cell Epitopes For Peptide-Based Immunotherapy. Blood, 2013, 122, 5431-5431.	1.4	0
100	NY-ESO-1 specific CD4⁺ T_{helper}1 cells for immunotherapy of cancer.. Journal of Clinical Oncology, 2014, 32, 3071-3071.	1.6	0
101	Generation of specific polyclonal and polyfunctional CD4⁺ T-helper1 cells against WT-1, MAGE-A3, Survivin and ROR-1 for adoptive T-cell immunotherapy.. Journal of Clinical Oncology, 2015, 33, e14025-e14025.	1.6	0
102	Transcutaneous Immunization with a Solid Nanoscopic Imiquimod Suspension Enhances Tumor Rejection. Blood, 2015, 126, 2224-2224.	1.4	0
103	Favorable Immune Signature in CLL Patients, Defined By Antigen-Specific T-Cell Responses, Might Prevent Secondary Skin Cancers. Blood, 2015, 126, 1722-1722.	1.4	0
104	Unique Alterations in the Immunopeptidome of Colorectal Cancer Reflect Specific Transformations in Cancer-Associated Signaling Pathways and Reveal Tumor-Specific HLA-Ligand Modulations. Blood, 2016, 128, 862-862.	1.4	0
105	Mass Spectrometry-Based Immunopeptidome Analysis of Acute Myeloid Leukemia Cells Under Decitabine Treatment Delineates Induced Presentation of Cancer/Testis Antigens on HLA Class I Molecules. Blood, 2018, 132, 5223-5223.	1.4	0